IPA (ImmunoPrecise Antibodies)

Press release: IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment. IPA has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSᵃⁱ™ platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience. "LENSᵃⁱ's continued breakthroughs underscore the unparalleled power of our HYFT patterns," said Dr. Jennifer Bath, CEO of IPA. "These patterns, which only IPA possesses, are the key to unlocking unprecedented speed and precision in biologics research. LENSᵃⁱ is not just accelerating development—it's redefining the very process of therapeutic innovation." See the full release: https://lnkd.in/ePjYPnFm #GLP1 #Innovation #DrugDiscovery

Fragmented data slowing down your drug discovery? It’s more common than you think. This week at #BioITWorld, we’re talking about the approximately 70% of researchers stuck wrangling incompatible datasets instead of driving innovation. The usual suspects: • Genomics, proteomics, and clinical data trapped in silos • Legacy systems that limit AI’s potential • Trial-and-error decisions caused by poor data alignment Here’s the shift: LENSᵃⁱ™, powered by BioStrand’s patented HYFT® technology, brings it all together by: • Offering a one-of-a-kind mult-omics fully integrated platform to uncover the unseen and expand the scope of your research • Stacking large language models that interpret biological context • Building knowledge graphs that uncover hidden protein–drug relationships “This isn’t just IT—it’s an R&D competitive edge.” – Dirk Van Hyfte, MD, Ph.D. — BioStrand`s Chief Technology Officer. We’re at Bio-IT World this week. Connect with Dirk to discuss how we can turn your data into real discovery: https://lnkd.in/geUC-WAA #BioIT2025 #AI #DrugDiscovery #MultiOmicsData BioStrand (a subsidiary of IPA)

Heading to Bio-IT World 2025 in Boston? Dirk Van Hyfte, MD, Ph.D., Head of Innovation, will be at BIO-IT from April 2-4, ready to chat about how LENSᵃⁱ™, powered by HYFTs, is making complex biological data work together for smarter #drugdiscovery. The challenge? Drug discovery depends on massive, disconnected datasets—genomics, proteomics, clinical data, literature. The solution? LENSᵃⁱ™ connects the dots: ✓ Faster AI-powered molecule design → Generative AI helps pinpoint novel candidates quicker. ✓ Seamless multi-modal integration → Genomics, proteomics, experimental data- finally in sync. ✓ Smarter workflows → AI-driven retrieval, RAG, and knowledge graphs deliver precision. ✓ Fewer costly experiments → Data-driven insights streamline decision-making. Looking for a better way to extract insights from your data? Let’s connect in Boston: https://lnkd.in/efHeZr-g #BioITWorld #Bioinformatics BioStrand (a subsidiary of IPA)

Press Release: IPA reports financial results for third quarter 2025. Details below to join the call today. Strength at Scale: AI Growth Accelerates "We're revolutionizing AI-enabled drug discovery with a strategic $8-10 million USD partnership, leveraging our B-cell Select technology. Amidst surging demand for therapeutic applications, our AI segment has achieved a remarkable 131.8% year-over-year revenue increase with a 97% gross profit margin. This positions us for sustainable growth and increased shareholder value." Dr. Jennifer Bath CEO and President IPA See full release: https://lnkd.in/gZ3jSq3H Join call - 10:30 am EST The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://lnkd.in/eVaabrPS. ***Participant Dial-In Details*** Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Canada - Toll-Free (800) 715-9871 ***Webcast Details*** Attendee URL: https://lnkd.in/g4Ec3WxV #Biotech #TechBio #AI #Antibodies #DrugDiscovery BioStrand (a subsidiary of IPA)

Wrapping up an inspiring NVIDIA GTC! The enthusiasm surrounding generative AI in drug discovery is a powerful validation of our shared commitment to innovation. Huge thanks to VULTR for inviting us to speak, present key challenges, and join an insightful panel discussion. As we continue to push the boundaries of innovation in healthcare, NVIDIA’s advancements in generative AI are transforming the drug discovery landscape. Key takeaways—reflecting our shared direction with the evolving future of drug discovery: • Accelerated Molecule Design: Generative AI tools enable researchers to explore vast chemical spaces, accelerating the identification of novel molecules and reducing development time. • Efficient Workflows: Integrated frameworks simplify AI deployment across platforms, scaling drug discovery efforts efficiently. • End-to-End Solutions: From target identification to lead optimization, AI models enhance precision in protein structure prediction and molecular generation. • Collaborative Innovation: Partnerships with biotech firms leverage AI to reduce reliance on costly experiments, potentially halving drug development costs. The future of healthcare innovation is here—let's leverage AI to solve the complex and deliver real breakthroughs. What are your thoughts on the future of drug discovery? Share your insights! NVIDIA Vultr #DrugDiscovery #Ai #Antibodies #Innovation BioStrand (a subsidiary of IPA) Jennifer Bath, Ph.D. Kamil Isaev Dirk Van Hyfte, MD, Ph.D. Frédéric Chabot Anthony Quon Amit Rai Jaeson Nicolopulos Dr. Eva-Maria Hempe J.J. Kardwell Eric Rosa Cedric Steenbeke Kasia Hilborne David Ruau

LIVE at NVIDIA GTC 2025! Yesterday, Dirk Van Hyfte, MD, Ph.D., took the stage to tackle a big question: How do we make AI truly bio-native for drug discovery? His talk and live demo showcased HYFT Technology, the AI-native framework powering LENSᵃⁱ™, designed to solve the four key challenges in drug discovery: ✔ AI bio-readiness– Transforming biology in an AI-ready format ✔ Unify sequence, structure, function & text – Cross-modal retrieval for deeper insights ✔ Scale efficiently – Smarter retrieval and real-time discovery ✔ Generalize knowledge – AI that evolves across biological contexts If you missed it, there’s still one more live booth presentation today! Vultr Booth (#1533) | March 20 | 4:00 PM Or let’s continue the conversation—schedule a live demo: https://lnkd.in/ehXUPWUj #GTC2025 #AIinBiology #DrugDiscovery #AntibodyDiscovery #NVIDIA #VULTR Vultr BioStrand (a subsidiary of IPA)

We’re live at NVIDIA GTC 2025! Jennifer Bath, Ph.D. (President & CEO, IPA), Dirk Van Hyfte, MD, Ph.D. Van Hyfte, M.D., Ph.D. (CTO & Co-Founder, BioStrand), and Frédéric Chabot (Head of Corporate Development, IPA) have arrived—stop by Vultr Booth (#1533) to see LENSᵃⁱ™ powered by HYFT technology in action and explore how AI is solving the four key challenges in drug discovery. Join the VLTR LinkedIn Live on March 19 at 5 PM PT Dirk Van Hyfte will be in conversation with Andrea Kinnison-DeMartino from Vultr, discussing AI breakthroughs in healthcare and what’s next in the field. Watch here: https://lnkd.in/gh9niNJM Live booth presentations at Vultr Booth (#1533): ✔ March 19 | 4:30 PM ✔ March 20 | 4:00 PM Can’t attend? Schedule a demo with our team: https://lnkd.in/ehXUPWUj Let’s connect at #GTC2025! #NVIDIA #AIinBiology #DrugDiscovery #AntibodyDiscovery Vultr BioStrand (a subsidiary of IPA)

BioStrand (a subsidiary of IPA) is heading to NVIDIA GTC 2025—the premier AI conference! Join us at the Vultr Booth (#1533) from March 17-20 and see LENSᵃⁱ™ powered by HYFT technology in action! LENSᵃⁱ isn’t just trained on biology—it’s engineered for it. With 25 billion+ biological connections, it drives multi-modal retrieval, deep biological context, and adaptive learning—making AI truly bio-native for #drugdiscovery. Live Presentation & Demo: HYFT Technology: AI-Native Biological Framework Solving the Four Key Challenges in AI-Driven Drug Discovery: ✔ AI bio-native readiness → AI that works with biology, not just statistical patterns ✔ Cross-modal retrieval → Seamlessly linking sequence, structure, function & text for a complete picture ✔ Scalability → Smarter retrieval and real-time discovery efficiency ✔ AI-driven knowledge generalization → AI that evolves and transfers insights across biological contexts Join our 15-minute booth presentation & live demo at NVIDIA GTC: - Wed, March 19 | 4:30 PM - Thu, March 20 | 4:00 PM - Dirk Van Hyfte, MD, Ph.D., CTO & Co-Founder Come by, see LENSᵃⁱ with HYFTs in action, and let’s talk about what’s next for AI in biology. #NVIDIA #GTC2025 #AIinBiology Jennifer Bath, Ph.D. Frédéric Chabot

Press Release: Exciting Partnership Announcement! ImmunoPrecise Antibodies (NASDAQ: IPA) has entered into an $8M-$10M (USD) strategic partnership with a global biotechnology leader to advance the discovery and development of next-generation Antibody-Drug Conjugates (ADCs) and bispecific antibodies for cancer treatment. This collaboration will leverage our industry-leading B-cell Select™ platform alongside our patented LENSᵃⁱ™ AI-driven discovery technology, enabling a highly efficient and data-driven approach to therapeutic antibody development. By integrating cutting-edge AI, multi-omics modeling, and proprietary antibody discovery workflows, we are setting a new standard in precision medicine and oncology drug development. This partnership represents a major milestone in our mission to accelerate breakthrough therapeutics that address critical unmet medical needs. Stay tuned for more updates as we push the boundaries of innovation in AI-driven biopharma solutions. See full release: https://lnkd.in/gKTasuvt BioStrand (a subsidiary of IPA) #Innovation #DrugDiscovery #Antibodies #AI #Biotechnology #ArtificialIntelligence #ADC #CancerResearch